{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000343.1:c.158C>T",
          "cDNA Change": {
            "transcript": "NM_000343.1",
            "ref": "C",
            "alt": "T",
            "position": "158"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "p.A53T associated with increased α-synuclein accumulation and early-onset Parkinson's disease"
        }
      ]
    },
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_181797.1:c.6056A>G",
          "cDNA Change": {
            "transcript": "NM_181797.1",
            "ref": "A",
            "alt": "G",
            "position": "6056"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "p.G2019S linked to elevated kinase activity and Parkinson's disease pathogenesis"
        }
      ]
    },
    {
      "Gene": "GBA",
      "variants": [
        {
          "HGVS": "NM_000168.2:c.1099A>T",
          "cDNA Change": {
            "transcript": "NM_000168.2",
            "ref": "A",
            "alt": "T",
            "position": "1099"
          },
          "Protein Change": {
            "ref": "N",
            "alt": "S",
            "position": "370"
          },
          "Description in input context": "p.N370S associated with reduced glucocerebrosidase activity and Parkinson's disease risk"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005067"
  },
  "Experiment Method": [
    {
      "Assay Method": "Western Blot",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "SH-SY5Y",
        "Description": "Western blot analysis was performed on SH-SY5Y cells overexpressing SNCA p.A53T."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000343.1:c.158C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "SNCA p.A53T showed 2.5-fold higher α-synuclein aggregation compared to wild-type."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were conducted."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was run in triplicate."
      },
      "Control": {
        "Control": "Wild-type SNCA",
        "Description": "Used as a reference for baseline α-synuclein levels."
      },
      "Statistical Analysis": {
        "Statistical Analysis": "ANOVA",
        "Description": "Significant differences (p < 0.01) were observed between wild-type and p.A53T variants."
      },
      "Threshold": {
        "Threshold": "1.5-fold increase",
        "Description": "Defined as abnormal aggregation levels."
      },
      "Approved assay": "Yes"
    },
    {
      "Assay Method": "CRISPR-Cas9",
      "Material used": {
        "Material Source": "Patient-derived fibroblasts",
        "Material Name": "LRRK2 G2019S fibroblasts",
        "Description": "CRISPR-Cas9 was used to knockout LRRK2 in patient-derived fibroblasts."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_181797.1:c.6056A>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "gain-of-function",
          "Result Description": "LRRK2 G20身S exhibited 40% higher kinase activity compared to wild-type."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Two biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not specified in the paper."
      },
      "Control": {
        "Control": "Wild-type LRRK2",
        "Description": "Used as a baseline for kinase activity."
      },
      "Statistical Analysis": {
        "Statistical Analysis": "t-test",
        "Description": "Significant increase (p < 0.05) in kinase activity for G2019S."
      },
      "Threshold": {
        "Threshold": "25% increase",
        "Description": "Defined as abnormal kinase activity."
      },
      "Approved assay": "Yes"
    },
    {
      "Assay Method": "Enzymatic Activity Assay",
      "Material used": {
        "Material Source": "Patient-derived lymphoblasts",
        "Material Name": "GBA N370S lymphoblasts",
        "Description": "Enzymatic activity of GBA was measured in patient-derived lymphoblasts."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000168.2:c.1099A>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "loss-of-function",
          "Result Description": "GBA N370S showed 60% reduced glucocerebrosidase activity compared to wild-type."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Four biological replicates were conducted."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was tested in duplicate."
      },
      "Control": {
        "Control": "Wild-type GBA",
        "Description": "Used as a reference for normal enzyme activity."
      },
      "Statistical Analysis": {
        "Statistical Analysis": "ANOVA",
        "Description": "Significant reduction (p < 0.001) in activity for N370S."
      },
      "Threshold": {
        "Threshold": "35% reduction",
        "Description": "Defined as abnormal enzymatic activity."
      },
      "Approved assay": "Yes"
    }
  ]
}